Are you interested in learning more about managing atopic dermatitis in specific patient groups? Look no further and listen to the DermTalks Podcast - Atopic Dermatitis in Special Populations!
Over the course of four episodes, dermatologists from North-European countries will focus on one specific group of patients.

Heeft u vragen of wilt u meer weten? Wij zorgen dat u zo snel mogelijk geholpen wordt.

Wij staan klaar

DermTalks Podcasts – Atopic Dermatitis in Special Populations

ATOPIC-DERMATITIS

DERMATOLOGY

The presence or risk of comorbidities can significantly impact the management of patients with atopic dermatitis (AD). This is why understanding the comorbidities associated with AD is crucial for effective management.
In this DermTalks podcast episode, Dr. Jon Anders Halvorsen, senior dermatologist and guest researcher at the University of Oslo, Norway, delves into the comorbidities associated with atopic dermatitis.

"In the care of patients with AD, it is important to pay attention to comorbidities. Treating the skin disease can potentially lower the risk of psychiatric comorbidities and skin infections1. Biologic treatments targeting IL-4/13 can be beneficial for patients with both AD and atopic comorbidities like asthma3."
Dr. Jon Anders Halvorsen 
 Dermatologist, Oslo, Norway

<h2>Key highlights</h2>
Understanding the comorbidities associated with AD is essential for several reasons. Firstly, it helps dermatologists better understand the patient's situation by recognizing associations and possible consequences of the disease. Secondly, it aids in choosing appropriate therapies for individual patients, as biologics and other targeted agents can simultaneously treat multiple conditions. Lastly, it encourages patients to seek help and be screened for comorbidities1,2.
<h4>Article of interest:</h4>
<a href="https://pubmed.ncbi.nlm.nih.gov/36621338/" target="_blank">Thyssen JP, et al. Comorbidities of atopic dermatitis - what does the evidence say? J Allergy Clin Immunol. 2023 May;151(5):1155-1162.</a>

<h3>Atopic Comorbidities</h3>
Patients with AD have a significantly increased likelihood of having other atopic diseases (3- to 4-fold increased odds)1. Furthermore, the atopic comorbidities are part of the diagnostic criteria of AD2.
Rhinitis is seen in about 4 out of 10 patients with AD1. Asthma is present about 2 out of 10 patients, with adults with AD being three times more likely to have asthma than those without AD1,2. Additionally, food reactions are established as a comorbidity of AD, while nasal polyposis and eosinophilic esophagitis, which share an immunological mechanism with AD, and may also be associated with AD, although the evidence is not certain1,2.
Biologics like dupilumab can help manage patients with some atopic comorbidities such as asthma, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis3.
<h3>Ocular Comorbidities</h3>
Ocular comorbidities are also part of the diagnostic criteria for AD. Conjunctivitis is seen in 31.7% of patients with AD, while blepharitis is present in 22% of patients. Less common ocular comorbidities include dry eyes, keratitis, cataract, and keratoconus1. However, the association between AD and these eye conditions is not well documented and remains uncertain2. In some cases, involving an ophthalmologist in patient care is necessary.
<h3>Psychiatric Comorbidities</h3>
Patients with AD have an increased risk of psychiatric conditions such as depression, anxiety, and suicidal behavior1,2. Many studies show a two-fold risk of these comorbidities2. There is also a possible, but uncertain association between AD and ADHD and autism2. The symptoms of AD, particularly itch and lack of sleep, as well as the psychosocial burden of the disease, likely contribute to these psychiatric conditions2. Additionally, the increased level of inflammation in AD may directly influence the brain4. Some studies indicate that treating AD can improve psychiatric comorbidities1,2. Using quality of life instruments like the DLQI can help address these issues in patients with AD.
<h3>Autoimmune Comorbidities</h3>
Alopecia areata is much more common in patients with AD, with probably a ten-fold increase in prevalence1. JAK inhibitors may be a good treatment option for patients with both AD and alopecia areata2,5. Vitiligo and urticaria are also more common in patients with AD, with a 1.5 to 2-fold increase in prevalence2. Other autoimmune diseases, such as bowel disease, lupus, and rheumatoid arthritis, are probably also more common in patients with AD1. However, type 1 diabetes is not associated with AD, and some studies suggest a lower risk in patients with AD1.
<h3>Cardiovascular Comorbidities</h3>
The relationship between AD and cardiovascular diseases is uncertain and their prevalence possibly only slightly elevated1,2. Hypertension, coronary artery disease, and peripheral artery disease have a small magnitude of association with AD2. Lifestyle factors like smoking and obesity are increased in some studies, but the evidence is low1. There is a probable but small magnitude of association between thromboembolic disease and AD2. This is noteworthy given the possible elevated risk for thromboembolic disease with JAK inhibitors compared to placebo5-7.
<h3>Infectious Comorbidities</h3>
Patients with AD have an increased risk of viral (herpes, warts) and bacterial (staphylococcus) infections, likely due to immunological causes and the disrupted skin barrier1,8. Poorly controlled dermatitis increases the likelihood of infections while targeted therapies that downregulate IL-4 and IL-13 signaling have been associated with improvements in multiple aspects of skin barrier structure and function, including reduction in trans-epidermal water loss, increased levels of barrier function proteins, and normalization of the skin microbiome2,9,10.
<h3>Contact Dermatitis</h3>
AD can affect the hands and be complicated by contact dermatitis, most commonly irritant contact dermatitis, but also allergic contact dermatitis. In patients with severe AD, the risk of allergic contact dermatitis is lower, possibly due to immunological reasons. Patch testing can be a relevant work-up in patients with AD.1
<h3>Bone Health Issues</h3>
Osteoporosis and fractures are probably increased in patients with AD, possibly due to lifestyle factors (tobacco smoking, physical inactivity) and treatment (especially systemic corticosteroids). Inflammation itself may also contribute1,2.
<h3>Cancer</h3>
Patients with AD have an increased risk of skin cancer (keratinocyte cancer), with a 1.3 to 1.5-fold increase in prevalence. This may be due to lower levels of photoprotection in AD, phototherapy, and systemic therapies. There is also a probable slight risk of lymphoma, but no evidence shows associations with other cancers1. In patients with previous cancers, the use of JAK inhibitors is generally contraindicated5-7.
<h3>Conclusion</h3>

In the care of patients with AD, it is important to pay attention to comorbidities. Treating the skin disease can potentially lower the risk of psychiatric comorbidities and skin infections1. Biologic treatments targeting IL-4/13 can be beneficial for patients with both AD and atopic comorbidities like asthma3. JAK inhibitors can improve other autoimmune diseases like rheumatoid arthritis and alopecia areata5-7.

CLICK HERE TO READ DUPIXENT COMPULSORY INFORMATION

Speaker : Dr. Jon Anders Halvorsen, Oslo, Norway

Managing Atopic Dermatitis in Patients with Comorbidities

Atopic dermatitis (AD) is a prevalent condition in the elderly, presenting unique challenges in diagnosis and treatment due to its varied presentation and the overall medical condition of the patients.
In this DermTalks podcast episode, Dr. Stine Simonsen, clinical associate professor at the university of Copenhagen and dermatologist at the Copenhagen University Hospitals in Denmark, shares her insights on managing atopic dermatitis in the elderly population.

"Atopic dermatitis is prevalent in the elderly and may present in this age group. Special considerations are necessary when treating elderly patients such as considering the patient's overall health, current medications and comorbidities are essential for effective management."
Dr. Stine Simonsen 
 Dermatologist, Copenhagen University Hospitals, Denmark

<h2>Key highlights</h2>
The elderly population is defined by the OECD as individuals aged 65 years and over, while the United Nations defines an older person as someone over 60 years of age. Atopic dermatitis in the elderly presents unique challenges in diagnosis due to its varied presentation. Also, when considering treatment in this population, it’s essential to account for the patient’s overall medical condition, current medications, and their general physical and mental health status.
<h4>Article of interest:</h4>
<a href="https://pubmed.ncbi.nlm.nih.gov/32086792/" target="_blank">Tanei R. Atopic Dermatitis in Older Adults: A Review of Treatment Options. Drugs Aging. 2020 Mar;37(3):149-160</a>

<h3>Prevalence of AD in the Elderly</h3>
AD is prevalent in the elderly, with onset and clinical course varying1. It may present as a new disease in older adults (senile onset), as a recurrence of childhood AD (outgrowth-recurrence form), or as a continuation and/or recurrence of adolescent/adult AD2. The prevalence in the elderly varies from 1.2% to 17.1% in studies, with a recent UK study showing a prevalence of 8.2% in adults aged 75-99 years1.
<h3>Incidence and Ethnic Differences</h3>
The incidence of AD in the elderly is 8 in 1000 person-years for individuals over 80 years, compared to 174 in 1000 person-years in children under 1 year in the UK. Senile onset AD is higher in males and in Black and Asian populations compared to White ethnic groups and is associated with lower socioeconomic status1.
<h3>Clinical Presentation in the Elderly</h3>
AD in the elderly does not have a single presentation1. It often manifests as chronic lichenified eczema on the upper body, similar to that seen in adolescents and young adults2. The "reverse sign," where the typical distribution of eczema is reversed, is more common in the elderly. AD in the elderly is less likely to affect the face and scalp and more likely to affect the buttocks or genitals. Refractory facial erythema, loss of the lateral eyebrows (Hertoghe sign), Dennie–Morgan infraorbital folds, and neck dermatitis are also observed2.
<h3>Diagnostic Challenges</h3>
Diagnosing AD in the elderly can be challenging due to the lack of clear diagnostic criteria. Traditional criteria, such as the UK Working Party or Hanifin and Raika, should be used2. When diagnosing AD in the elderly, it is essential to exclude other pruritic skin disorders, such as cutaneous T-cell lymphoma, asteatotic dermatitis, nummular eczema, contact dermatitis, chronic prurigo, adverse drug reactions, scabies, Ofuji disease (in Japanese), chronic eczematous eruption of aging, and eczematous variants of bullous pemphigoid2. Extra attention to treatment of refractory disease is needed, and cutaneous T cell lymphoma must be ruled out by histopathology, since this diagnosis should be excluded before initiating any systemic therapy2,4.
<h3>Immune Mechanisms</h3>
Adult-onset AD patients may be less likely to have IgE-specific allergies and filaggrin mutations compared to childhood-onset AD1. In elderly patients with high serum total IgE, Th2 cytokines (IL-4, IL-5, and IL-13) dominate in peripheral blood, while Th1 cytokines (IFN-γ) dominate in those with low serum total IgE. In the skin, elderly patients with AD show decreased Th2 and Th22 cytokines and increased Th1 cytokines in lesional skin compared to adult AD patients2.
<h3>Considerations for Treatment</h3>
When choosing therapies for elderly patients, considerations include cognitive ability, functional independence, ability to self-administer medication, renal function, comorbidities, polypharmacy, and drug interactions2-4. Data supporting treatment choices for elderly patients with AD are limited due to their exclusion from trials (upper age limit or comorbidities). A systematic review of randomized controlled trials (RCTs) from 2020 of systemic immunomodulatory treatments for AD, found that in the trials reporting proportion of participants aged 65 or older, 4% were 65 or older5.
Comorbidities such as heart disease, cerebrovascular disease, diabetes mellitus, chronic renal disease, and osteoporosis and pharmacological interactions must be considered when starting systemic treatment3.
<h4>1. Topical therapies</h4>
Basic treatment is similar to other age groups, however, applying sufficient topical medication may be difficult or even become a burden. Therefore, solutions to this challenge should be considered, including help from relatives or community-based caregivers2.
<h4>2. Phototherapy</h4>
Phototherapy may be burdensome or even impossible for some elderly patients due to the number of visits needed per week2,3.
<h4>3. Systemic Therapies</h4>
Traditional systemic therapies are effective in the elderly, but due to comorbidities, the risk of skin cancer, and the risk of infection, cyclosporine, azathioprine, and mycophenolate mofetil are not the best choices. Methotrexate may be considered, but it is advised to use a lower starting dose2-4,14-17.
<h4>4. Biologics</h4>
Biologics such as dupilumab and tralokinumab are reasonable treatment options, with data showing similar efficacy in the elderly as in other age groups6,8. These treatments are well tolerated, no routine screening and monitoring are required, and no interactions are known9,10.
<h4>5. Janus Kinase Inhibitors</h4>
JAK inhibitors are indicated for elderly patients with AD, but caution is needed in patients over 65 years of age due to the higher risk of serious infections, cardiovascular disease, malignancies, thromboembolic events, and mortality. For those patients, a lower starting dose is indicated, and careful monitoring is recommended, alongside with screening for risk factors such as increased cardiovascular events, increased risk of cancer, and smoking11-13.
<h3>Conclusion</h3>

Atopic dermatitis is prevalent in the elderly and may present in this age group. Like pediatric AD or adult AD, it is driven by a Th2 pathway. Special considerations are necessary when treating elderly patients such as considering the patient's overall health and comorbidities are essential for effective management.

CLICK HERE TO READ DUPIXENT COMPULSORY INFORMATION

Speaker : Dr. Stine Simonsen, Copenhagen University Hospitals, Denmark

Managing Atopic Dermatitis in the Elderly

Managing atopic dermatitis (AD) in specific patient groups, such as pregnant and breastfeeding women, requires a careful benefit-risk balance. Indeed, it’s crucial to approach this population with a ‘safety first’ mindset, prioritizing the well-being of both the mother and the developing fetus, as well as balancing the importance of a well-controlled disease.
In this DermTalks podcast episode, Dr. Klas Agerberg discusses an expert consensus “Systemic anti-inflammatory treatment of atopic dermatitis during conception, pregnancy, and breastfeeding: Interdisciplinary expert consensus in Northern Europe” published in 2024 in the Journal of the European Academy of Dermatology and Venereology1. This consensus, crafted by leading experts in Northern Europe, offers valuable guidelines for managing AD with systemic anti-inflammatory treatments during conception, pregnancy, and breastfeeding.

"Individualized treatment plans, patient education, and interdisciplinary collaboration are essential for achieving optimal outcomes. Dermatologists should prioritize effective medications with low-risk profiles and support mothers in their decisions regarding treatment and breastfeeding."
Dr. Klas Agerberg 
 Dermatologist, Uppsala University Hospital, Sweden

<h2>Key highlights</h2>
Treating AD during pregnancy involves navigating the ethical challenges of clinical trials in pregnant women, as current guidelines deem it unethical to perform such trials. Consequently, there is a lack of high-level evidence on the efficacy and safety of systemic treatments in this population. The consensus emphasizes the importance of patient education and individualized advice, ideally in collaboration with an obstetrician1.
<h4>Article of interest:</h4>
<a href="https://pubmed.ncbi.nlm.nih.gov/37818828/" target="_blank">Deleuran M. et al, Systemic anti-inflammatory treatment of atopic dermatitis during conception, pregnancy, and breastfeeding: Interdisciplinary expert consensus in Northern Europe. J Eur Acad Dermatol Venereol. 2024 Jan;38(1):31-41</a>

<h3>Pre-pregnancy and AD Management</h3>
Guidance for Women: Effective planning and treatment are crucial during the pre-pregnancy phase to manage AD and minimize risks. Cyclosporine A is recommended as the first-choice treatment due to its favorable risk-benefit profile, although it requires close monitoring for renal impairment and arterial hypertension1. Short courses of prednisolone are also considered relatively safe for acute flares1. Regarding second line systemics, there is no specific recommendation for biologics during pre-conception in the product SmPC. However, the experts thought that women should avoid JAK inhibitors, methotrexate, and mycophenolate mofetil pre-conception, with appropriate washout periods1. Specific recommendations for contraception during and after treatment with these drugs are provided in their summary of product characteristics5-7. Women of child-bearing potential should be advised to use effective contraception during treatment and for 4 weeks following the final dose of any JAKi treatment8.
Guidance for Men: For men planning to conceive, cyclosporine A, azathioprine, and corticosteroids are suggested as appropriate options, with no significant effect on male fertility1. Dupilumab may also be used despite limited information on its effects on male fertility1. Animal studies showed no impairment of fertility and fertility studies conducted in male and female mice using a surrogate antibody against IL-4Ra showed no impairment of fertility2. Methotrexate and mycophenolate mofetil are discouraged due to potential adverse effects on sperm, and the data on JAK inhibitors are scarce, and the experts reached no consensus on their use in men wishing to conceive1.
<h3>Pregnancy and AD Management</h3>
Effective management of AD during pregnancy is necessary to maintain maternal quality of life and prevent severe symptoms. This consensus supports the use of systemic therapies when the benefits outweigh potential risks for the fetus. Furthermore, physicians should consider systemics if AD is severe and topical therapies or UVB are inadequate. A collaborative approach involving dermatologists and obstetricians is crucial for optimizing outcomes1.
Cyclosporine A is the preferred long-term systemic treatment during pregnancy and short courses of prednisolone are recommended for flare management and with acceptable safety for short-term use. However, those therapies should not be used during pregnancy unless the potential benefit to the mother justifies the potential risk to the fetus.1,9,10
The experts reached no consensus on biologics as there is a limited amount of data from the use of dupilumab, tralokinumab and lebrikizumab in pregnant women1.
<ul>
 <li>Dupilumab product SmPC mentions that the animal studies did not indicate direct or indirect harmful effects with respect to reproductive toxicity, and that dupilumab should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus2. 
 &nbsp;</li>
 <li>Tralokinumab and lebrikizumab product SmPC mention that as a precautionary measure, it is preferable to avoid the use of tralokinumab and lebrikizumab during pregnancy3,4.</li>
</ul>
JAK inhibitors, methotrexate, and mycophenolate mofetil are contraindicated during pregnancy due to their teratogenic effects. The consensus strongly advises against their use to prevent fetal harm1.
<h3>Breastfeeding and AD Management</h3>
The World Health Organization advocates for breastfeeding due to its numerous benefits for both mother and child. The consensus supports accommodating mothers who wish to breastfeed while managing AD. This decision should always be made in collaboration with the patient. Similar as for previous stages, the safety of both the mother and the infant is paramount when selecting systemic AD treatments, and in certain cases, prioritizing the control of AD over breastfeeding might be necessary1.
Cyclosporine A is highlighted as the first-choice treatment during breastfeeding due to its established safety and efficacy, with prednisolone recommended for flares1.
The safety of newer biologics during breastfeeding is not well-established, and a decision must be made whether to discontinue breastfeeding or the biologic therapy based on the benefits and risks1. It is unknown whether newer biologics are excreted in human milk or absorbed systemically after ingestion2. The excretion in breast milk should be small due to dupilumab high molecular weight; however, more studies need to be conducted to determine its effects during lactation8.
Similar to pregnancy, JAK inhibitors, methotrexate, azathioprine, and mycophenolate mofetil should be avoided during breastfeeding due to potential risks to the infant1.
<h3>Conclusion</h3>

Managing atopic dermatitis in pregnant and breastfeeding women requires a careful balance of safety and efficacy. A shared-care framework involving dermatologists and obstetricians is crucial for optimizing outcomes for both mother and infant1. This approach ensures coordinated management and supports informed and shared decision-making with the patient. Individualized treatment plans, patient education, and interdisciplinary collaboration are essential for achieving optimal outcomes. Dermatologists should prioritize effective medications with low-risk profiles and support mothers in their decisions regarding treatment and breastfeeding.

Speaker : Dr. Klas Agerberg, Uppsala University Hospital, Sweden

Managing Atopic Dermatitis During Pregnancy and Breastfeeding

PREVIOUS EPISODE
<h2>Polyp Gossip – Episode 2: Scent-sational Secrets: The Smell Loss Truth</h2>

We explore the impact of smell impairment and its connection to CRSwNP. Featuring insights from our hosts and a special guest, we uncover pathways to recovery and improved quality of life.

Surgical Whispers: is One Surgery Enough Before Biologics?

Living with CRSwNP: Daily Challenges and Solutions

<h2>Biography</h2>
<h3>Wytske Fokkens</h3>
Wytske J. Fokkens, MD, PhD, is a Professor at the Department of Otorhinolaryngology at the Academic Medical Center in Amsterdam. She is the Director of the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) Innovation Forum, Chairperson of the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS), and a member of the European Rhinologic Society Foundation Committee.&nbsp;
Prof. Fokkens is a founding member of EUFOREA, member of the Allergic Rhinitis and its Impact on Asthma Initiative, which develops guidelines for the management of concurrent allergic rhinitis and asthma, and center leader for the Global Allergy and Asthma European Network, a consortium of leading European research centers specializing in allergic diseases. She received the 2015 Paul Ehrlich Award for Experimental Research from the European Academy of Allergy and Clinical Immunology (EAACI) in 2015 and is an honorary member of EAACI, the Spanish and Greek Societies of Otorhinolaryngology, and the Romanian Rhinologic Society.&nbsp;
Prof. Fokkens is the author of more than 500 peer-reviewed papers on allergy and rhinology. Her main field of interest is sinus surgery and mucosal pathology of the upper and lower airways. She has written a textbook on rhinology and skull base surgery and has led an advanced sinus surgery course for more than 15 years. She serves as Editor-in-Chief of&nbsp;Rhinology&nbsp;and Associate Editor of&nbsp;Allergy.
<h3>Peter Hellings</h3>
Peter W. Hellings, MD, PhD, is a Professor and Clinic Head at the Department of Otorhinolaryngology at the University Hospitals of Leuven, and a Guest Professor at Ghent University, Belgium.
Prof. Hellings' research has led to novel insights into the pathophysiology of allergy and chronic airway inflammation, with over 350 scientific publications in top journals in the field of allergology, rhinology, and respiratory care. He is the founder of the European Forum for Research and Education in Allergy and Airway Diseases, an international nonprofit involving a consortium of European key opinion leaders aiming at the implementation of optimal care for chronic respiratory diseases. He is also the founder and director of the European Rhinoplasty Course and a member of European and American guideline committees.

We explore the impact of smell impairment and its connection to CRSwNP. Featuring insights from our hosts and a special guest, we uncover pathways to recovery and improved quality of life.

Polyp Gossip – Episode 2

CHRONIC-RHINOSINUSITIS-WITH-NASAL-POLYPS-CRSWNP

RESPIRATORY

In deze live talkshow gaan experts met elkaar in discussie over de impact van een ernstige RSV-infectie op baby's, ouders en de maatschappij. Daarnaast wordt er aandacht besteed aan preventieve mogelijkheden en hoe deze in te zetten in de praktijk.

<h2>Samenvatting</h2>
Deze talkshow was live te volgen op 8 oktober j.l. en is nu on-demand beschikbaar.
Door middel van duidelijke uitleg, praktische voorbeelden en relevante discussies informeren moderator dr. de Vrankrijker en haar gasten u over alles wat u als zorgverlener moet weten over RSV bij baby’s.
De talkshow start met herkenning van RSV. Ervaringsverhalen illustreren het snelle beloop, de ernst en de gevolgen van de ziekte op korte en lange termijn.
Daarnaast wordt ingegaan op het belang van goede communicatie tussen zorgprofessionals en ouders over de preventie van RSV. De talkshow sluit af met voorbeeldgesprekken met ouders over immunisatie van baby's.
<h2>Sprekers</h2>

<ul>
	<li>dr.Lieke de Vrankrijker, Kinderarts infectieziekten-Immunologie @ UMC Utrecht</li>
</ul>

<ul>
	<li>Albert J. van der Veer, huisarts @ Huisartsenpraktijk Orion Bilthoven</li>
	<li>Sarah Hak, arts-onderzoeker @ Wilhelmina Kinderziekenhuis</li>
</ul>

<ul>
	<li>Sanne Bokkers, verloskundige @ Verloskundigen Aandelaak</li>
	<li>Ber Oomen, Executive Director @ European Specialist Nurses Organisation</li>
</ul>

<h2>Inhoud van het on-demand programma</h2>
<ol>
 <li>Introductie (5:40 min)</li>
 <li>Herkenning (32:48 min)</li>
 <li>Over RSV (22:15 min)</li>
 <li>Preventie (17:07 min)</li>
 <li>Communicatie (23:15 min)</li>
</ol>
<h2>Leerdoelen</h2>

<ul>
 <li>U herkent de symptomen van een mogelijke RSV-infectie bij jonge kinderen/baby’s 
 &nbsp;</li>
 <li>U weet waar u op moeten letten om een inschatting te kunnen maken van de ernst van RSV 
 &nbsp;</li>
 <li>U kent de ziektelast van RSV en de mogelijke lange termijn gevolgen 
 &nbsp;</li>
 <li>U bent op de hoogte van de grote lijnen van het rapport van de Gezondheidsraad met betrekking tot RSV-immunisatie 
 &nbsp;</li>
 <li>U kent enkele adviezen ten aanzien van communicatie met ouders rondom immunisatie</li>
</ul>

Het on demand programma is geaccrediteerd voor:
<ul>
 <li>Huisartsen (ABC1)</li>
 <li>Kinderartsen (NVK)</li>
 <li>Verloskundigen (KNOV)</li>
</ul>

RESPIRATORY-SYNCYTIAL-VIRUS

VACCINES

BEKIJK HIER DE TALKSHOW

FTO Online - On demand nascholing - RSV in de eerste lijn: Herkenning en preventie

The podcast explores advancements and challenges in managing atopic dermatitis, featuring insights from Dr. Diamant Thaci, a noted expert in inflammation medicine. It discusses the importance of interdisciplinary care and the evolution from general dermatological practice to specialized clinics. The conversation highlights how distinguishing comorbidities and understanding cytokines like IL-4 and IL-13 can improve treatment. Dr. Thaci emphasizes early and systemic treatments for better outcomes and discusses the potential for disease remission through future therapies. The ultimate goal is achieving patient-centered care and potentially altering the disease trajectory.

Hot topics in atopic dermatitis: Longterm Control in AD

LISTEN FOR MORE PODCASTS

PREVIOUS EPISODE
<h2>Polyp Gossip – Episode 1: Surgical Whispers: Is One Surgery Enough Before Starting Biologics?</h2>

Welcome to the debut episode of Polyp Gossip! In this episode, our expert panel explores a critical question in CRSwNP management: Is one surgery enough before starting biologics?

Scent-sational Secrets: The Smell Loss Truth

Welcome to the debut episode of Polyp Gossip! In this episode, our expert panel explores a critical question in CRSwNP management: Is one surgery enough before starting biologics?

Polyp Gossip – Episode 1

We are pleased to share the recording of the DermTalks webinar “Atopic Dermatitis in Melanin-Rich Skin” featuring Dr. Andrew Alexis, leading US dermatologist and global expert in dermatology for skin of color. In this session, moderated by Dr. Martta Jokinen, dermatologist from the DermTalks Board, Dr. Alexis delves into the complexities of atopic dermatitis (AD) across various skin types.
Watch the recording to gain valuable insights into the management of atopic dermatitis across different skin types.

Atopic Dermatitis in Melanin-Rich Skin – A DermTalks Webinar

<ul>
 <li>Classification of skin types</li>
 <li>Prevalence of AD in different skin types</li>
 <li>Presentation of AD in melanin-rich and other skin types</li>
 <li>Cytokine profiles in different skin types with AD</li>
 <li>Clinical evaluation of AD in melanin-rich skin</li>
 <li>Treatment aspects of AD in melanin-rich skin</li>
 <li>Treatment outcomes of AD in different skin types</li>
 <li>Future research needs on AD in melanin-rich skin</li>
</ul>

Dr. Andrew F. Alexis, MD, MPH, is the Vice-Chair for Diversity and Inclusion for the Department of Dermatology and Professor of Clinical Dermatology at Weill Cornell Medical College in New York City. With over 15 years of experience as the Director of the first-of-its-kind Skin of Color Center, Dr. Alexis has significantly advanced patient care, research, and education related to dermatologic disorders prevalent in populations with skin of color.

<h2>DermTalks Board</h2>
This webinar is part of the DermTalks Series 2.0, an unbranded educational initiative by Sanofi. The series is led by a board of dermatologists and aims to address current challenges, data gaps, and emerging trends in dermatology across North-European countries.

<h2>Helpful resources for the management of atopic dermatitis in skin of color</h2>
<ul>
 <li>Silverberg JI, Horeczko J, Alexis A. Development of an Eczema Area and Severity Index Atlas for Diverse Skin Types. Dermatitis. 2023 Jun 6:&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/37279030/">Development of an Eczema Area and Severity Index Atlas for Diverse Skin Types - PubMed</a> 
 &nbsp;</li>
 <li>Skin of Color Society Website – Textbooks or educational resources on skin of color:&nbsp;<a href="https://skinofcolorsociety.org/">Home - Main Landing Page - Skin of Color Society</a>
 <ul>
 <li>Textbooks:&nbsp;<a href="https://skinofcolorsociety.org/search-results/uncategorised/skin-of-color-dermatology-textbooks?highlight=WyJ0ZXh0Ym9vayJd">Skin of Color Dermatology Textbooks - Skin of Color Society</a></li>
 <li>Educational resources:&nbsp;<a href="https://skinofcolorsociety.org/discover-patients-public/educational-showcase">Educational Showcase - Skin of Color Society</a> 
 &nbsp;</li>
 </ul></li>
 <li>Journal of the American academy of dermatology (JAAD) - Searchable Atlas for dermatology conditions in melanin-rich skin:&nbsp;<a href="https://www.jaad.org/collection-skin-of-color-images">Skin of Color Image Atlas: Journal of the American Academy of Dermatology</a> 
 &nbsp;</li>
 <li>JEACP special issue: Skin Diversity:&nbsp;<a href="https://eadv.org/2024/07/22/jeacp-special-issue-skin-diversity/">JEACP special issue: Skin Diversity | EADV Publication</a></li>
</ul>

Voor uw intercontext, meld u aan bij uw account Sanofi Campus. Geef uw e-mail door aan uw e-mail.

Als u onze eerste e-mail op {email} tot bevestig uw account u kunt hieronder een nieuwe aanvragen. Als je het niet ziet, moet je mogelijk je spammap controleren.

Deze informatie wordt alleen gebruikt om uw account te valideren en wordt niet verspreid.

titel

Title

This website is for healthcare professionals only.

Welcome to BP Sanofi Campus

Create new password

Om u een gepersonaliseerde ervaring te bieden, moet u

Je profiel is onvolledig

De ADCT geeft een indicatie van hoe gecontroleerd het eczeem is. Beantwoord deze 6 eenvoudige vragen met uw patiënt om de ADCT-score te vinden. Het zal de juiste handelwijze aangeven.

Atopische dermatitis, een vorm van eczeem, kan het leven van uw patiënt op meer manieren beïnvloeden dan u weet.

Doe de atopische dermatitis controle test (ADCT)

Geniet van meer exclusieve inhoud{newline}door <a>door u vandaag te registreren</a>

Heb je al een account? <a>Hier inloggen</a>

Best practices voor het optimaliseren van de patiëntenzorg

Krijg een aangepast beeld van de onderwerpen waarin u geïnteresseerd bent, samen met de mogelijkheid om inhoud op te slaan om op een later tijdstip te bekijken of te lezen.

Onbeperkte toegang tot eersteklas inhoud, whitepapers, casestudy's, onderzoekspapers, webinars, training en up-to-date wetenschappelijke medische bronnen.

Gepersonaliseerde inhoud op basis van uw interessegebieden

Maak contact en blijf up-to-date met collega's op uw vakgebied en onderwerpen die u interesseren via gratis evenementen en leidinggevende forums.

Registreer om het volledige artikel te lezen.

Wij respecteren uw privacy en zullen uw informatie niet delen met derden.

Actuele gidsen die speciaal voor patiënten zijn geschreven

Onbeperkte toegang tot de nieuwste patiëntengidsen en bronnen. Deel inhoud met uw patiënten met gebruiksvriendelijke online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Beperkte toegang

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

Normaal gesproken bieden we een schat aan kenis, maar we konden niet vinden waar je naar op zoek bent.

We konden niet vinden wat je zocht

Sanofi is niet verantwoordelijk voor de inhoud van deze externe website.

U staat op het punt Campus.sanofi/nl te verlaten.

Images from <a>iStockphoto.com</a>, Fotolia.de, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

Volg ons:

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

Sanofi biedt u exclusieve content over onze verschillende therapeutische gebieden op één portal speciaal voor professionals in de gezondheidszorg, inclusief wetenschappelijk nieuws, een lijst met evenementen en tools en diensten voor uw dagelijkse praktijk.

Bevestig uw status

Welcome to ITP Sanofi Campus

De inhoud van deze website is alleen toegankelijk voor geregistreerde gebruikers.

Log in alstublieft

Email verificatie

U ziet een voorbeeld van de portal. Wis uw cookies (bijvoorbeeld door uw browservenster te sluiten) om terug te gaan naar de openbare modus.

We hebben onze privacyverklaring bijgewerkt om je gegevens beter te beschermen en je ervaring te verbeteren. Neem even de tijd om de wijzigingen door te nemen door <privacyNewTab>hier te klikken</privacyNewTab>. Uw privacy is belangrijk voor ons. Klik op doorgaan om te bevestigen dat u de nieuwe privacyverklaring hebt gelezen.

Update van de privacyverklaring

Communicatie toestemming

My consents

Password

Confirm password

{resultsCount, plural, one {resultaat} other {resultaten}}

Log in om toegang te krijgen tot de resultaten

U moet inloggen op uw account om toegang te krijgen tot medische inhoud.

Inloggen

Registreer in minder dan 1 minuut om toegang te krijgen tot de resultaten

U verlaat nu het Sanofi inhoudsgedeelte van onze site en komt in het inhoudsgedeelte voor extern medisch bibliografisch zoeken.

U verlaat nu het externe medische bibliografische zoekgedeelte van onze site en komt in het inhoudsgedeelte van Sanofi.

Educatie